WO2003097872A2 - Procede in-vitro permettant de detecter des lesions colorectales - Google Patents
Procede in-vitro permettant de detecter des lesions colorectales Download PDFInfo
- Publication number
- WO2003097872A2 WO2003097872A2 PCT/EP2003/050185 EP0350185W WO03097872A2 WO 2003097872 A2 WO2003097872 A2 WO 2003097872A2 EP 0350185 W EP0350185 W EP 0350185W WO 03097872 A2 WO03097872 A2 WO 03097872A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- detection
- cdna
- colorectal
- polypeptides
- Prior art date
Links
- 230000003902 lesion Effects 0.000 title claims abstract description 132
- 239000003550 marker Substances 0.000 title claims description 64
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title claims description 37
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 191
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 175
- 229920001184 polypeptide Polymers 0.000 claims abstract description 167
- 238000000034 method Methods 0.000 claims abstract description 122
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 87
- 238000001514 detection method Methods 0.000 claims abstract description 85
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 80
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 80
- 230000014509 gene expression Effects 0.000 claims abstract description 72
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 54
- 201000010099 disease Diseases 0.000 claims abstract description 31
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 19
- 238000000338 in vitro Methods 0.000 claims abstract description 12
- 238000004393 prognosis Methods 0.000 claims abstract description 11
- 238000002255 vaccination Methods 0.000 claims abstract description 11
- 238000013399 early diagnosis Methods 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 117
- 210000001519 tissue Anatomy 0.000 claims description 80
- 210000004027 cell Anatomy 0.000 claims description 76
- 150000001875 compounds Chemical class 0.000 claims description 74
- 206010028980 Neoplasm Diseases 0.000 claims description 73
- 102000004169 proteins and genes Human genes 0.000 claims description 73
- 235000018102 proteins Nutrition 0.000 claims description 71
- 239000000523 sample Substances 0.000 claims description 50
- 238000009739 binding Methods 0.000 claims description 43
- 230000027455 binding Effects 0.000 claims description 42
- 238000006243 chemical reaction Methods 0.000 claims description 38
- 239000002299 complementary DNA Substances 0.000 claims description 33
- 108020004999 messenger RNA Proteins 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 27
- 108091007433 antigens Proteins 0.000 claims description 27
- 102000036639 antigens Human genes 0.000 claims description 27
- 102000040430 polynucleotide Human genes 0.000 claims description 26
- 108091033319 polynucleotide Proteins 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 26
- 238000012360 testing method Methods 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 206010009944 Colon cancer Diseases 0.000 claims description 18
- 102100037932 Ubiquitin D Human genes 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 239000011230 binding agent Substances 0.000 claims description 16
- 108010029485 Protein Isoforms Proteins 0.000 claims description 15
- 102000001708 Protein Isoforms Human genes 0.000 claims description 15
- 238000003745 diagnosis Methods 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000009169 immunotherapy Methods 0.000 claims description 11
- 238000001574 biopsy Methods 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 10
- 230000017205 mitotic cell cycle checkpoint Effects 0.000 claims description 10
- 238000003384 imaging method Methods 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 8
- 102100029184 Calmodulin regulator protein PCP4 Human genes 0.000 claims description 7
- 239000000816 peptidomimetic Substances 0.000 claims description 7
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 101150025562 PCP4 gene Proteins 0.000 claims description 6
- 238000011065 in-situ storage Methods 0.000 claims description 6
- 230000002779 inactivation Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 102100024420 39S ribosomal protein S30, mitochondrial Human genes 0.000 claims description 5
- 102100038687 5'-nucleotidase domain-containing protein 3 Human genes 0.000 claims description 5
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 5
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 claims description 5
- 102100023777 60S ribosomal protein L31 Human genes 0.000 claims description 5
- 102100026926 60S ribosomal protein L4 Human genes 0.000 claims description 5
- 101710117426 60S ribosomal protein L4 Proteins 0.000 claims description 5
- 102000007469 Actins Human genes 0.000 claims description 5
- 108010085238 Actins Proteins 0.000 claims description 5
- 102100026608 Aldehyde dehydrogenase family 3 member A2 Human genes 0.000 claims description 5
- 101710130646 Aldehyde dehydrogenase family 3 member A2 Proteins 0.000 claims description 5
- 102100026424 Arrestin domain-containing protein 3 Human genes 0.000 claims description 5
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 5
- 101100494319 Caenorhabditis elegans bub-3 gene Proteins 0.000 claims description 5
- 102000014914 Carrier Proteins Human genes 0.000 claims description 5
- 102100025597 Caspase-4 Human genes 0.000 claims description 5
- 102100026548 Caspase-8 Human genes 0.000 claims description 5
- 108010075016 Ceruloplasmin Proteins 0.000 claims description 5
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 5
- 102100031634 Cold shock domain-containing protein E1 Human genes 0.000 claims description 5
- 101710124441 Cold shock domain-containing protein E1 Proteins 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 102100039216 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 2 Human genes 0.000 claims description 5
- 101100006503 Drosophila melanogaster Cks30A gene Proteins 0.000 claims description 5
- 102100022887 GTP-binding nuclear protein Ran Human genes 0.000 claims description 5
- 102100028541 Guanylate-binding protein 2 Human genes 0.000 claims description 5
- 101710110789 Guanylate-binding protein 2 Proteins 0.000 claims description 5
- 101000604531 Homo sapiens 5'-nucleotidase domain-containing protein 3 Proteins 0.000 claims description 5
- 101000785775 Homo sapiens Arrestin domain-containing protein 3 Proteins 0.000 claims description 5
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 5
- 101000933112 Homo sapiens Caspase-4 Proteins 0.000 claims description 5
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 claims description 5
- 101000620756 Homo sapiens GTP-binding nuclear protein Ran Proteins 0.000 claims description 5
- 101000581803 Homo sapiens Lithostathine-1-beta Proteins 0.000 claims description 5
- 101000896484 Homo sapiens Mitotic checkpoint protein BUB3 Proteins 0.000 claims description 5
- 101000998855 Homo sapiens Nicotinamide phosphoribosyltransferase Proteins 0.000 claims description 5
- 101001090901 Homo sapiens Retroelement silencing factor 1 Proteins 0.000 claims description 5
- 101000694973 Homo sapiens TATA-binding protein-associated factor 172 Proteins 0.000 claims description 5
- 101000658581 Homo sapiens Transmembrane 4 L6 family member 4 Proteins 0.000 claims description 5
- 108010064052 Interferon-Stimulated Gene Factor 3 Proteins 0.000 claims description 5
- 102000014746 Interferon-Stimulated Gene Factor 3 Human genes 0.000 claims description 5
- 102000008070 Interferon-gamma Human genes 0.000 claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 5
- 102100027338 Lithostathine-1-beta Human genes 0.000 claims description 5
- 102100021718 Mitotic checkpoint protein BUB3 Human genes 0.000 claims description 5
- 101000851075 Mus musculus Eukaryotic translation initiation factor 3 subunit E Proteins 0.000 claims description 5
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 claims description 5
- 102100023058 NHP2-like protein 1 Human genes 0.000 claims description 5
- 101710177157 NHP2-like protein 1 Proteins 0.000 claims description 5
- 102100033223 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims description 5
- 108010044843 Peptide Initiation Factors Proteins 0.000 claims description 5
- 102000005877 Peptide Initiation Factors Human genes 0.000 claims description 5
- 102100034981 Retroelement silencing factor 1 Human genes 0.000 claims description 5
- 108090000180 Ribosomal protein L31 Proteins 0.000 claims description 5
- 102000010983 Ribosomal protein S13 Human genes 0.000 claims description 5
- 108050001197 Ribosomal protein S13 Proteins 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- 108010091120 TATA-Binding Protein Associated Factors Proteins 0.000 claims description 5
- 102000018068 TATA-Binding Protein Associated Factors Human genes 0.000 claims description 5
- 102100028639 TATA-binding protein-associated factor 172 Human genes 0.000 claims description 5
- 102100034897 Transmembrane 4 L6 family member 4 Human genes 0.000 claims description 5
- 108091005906 Type I transmembrane proteins Proteins 0.000 claims description 5
- 101710138219 Ubiquitin D Proteins 0.000 claims description 5
- 238000003782 apoptosis assay Methods 0.000 claims description 5
- 108091008324 binding proteins Proteins 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- 229940044627 gamma-interferon Drugs 0.000 claims description 5
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 5
- 108010026689 mammalian protein p52 Proteins 0.000 claims description 5
- 210000002464 muscle smooth vascular Anatomy 0.000 claims description 5
- 230000005522 programmed cell death Effects 0.000 claims description 5
- 108010074916 ribophorin Proteins 0.000 claims description 5
- 230000014621 translational initiation Effects 0.000 claims description 5
- 108091005703 transmembrane proteins Proteins 0.000 claims description 5
- 102000035160 transmembrane proteins Human genes 0.000 claims description 5
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102100039788 GTPase NRas Human genes 0.000 claims description 4
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 4
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 208000007660 Residual Neoplasm Diseases 0.000 claims description 3
- 210000000941 bile Anatomy 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 abstract description 6
- 210000001072 colon Anatomy 0.000 description 26
- 210000001744 T-lymphocyte Anatomy 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 230000004075 alteration Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000002163 immunogen Effects 0.000 description 15
- 101000662056 Homo sapiens Ubiquitin D Proteins 0.000 description 13
- 230000002159 abnormal effect Effects 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 108091023040 Transcription factor Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 238000013461 design Methods 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 102100034001 DNA replication licensing factor MCM5 Human genes 0.000 description 8
- 101001017545 Homo sapiens DNA replication licensing factor MCM5 Proteins 0.000 description 8
- 229920001213 Polysorbate 20 Polymers 0.000 description 8
- 239000012190 activator Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- 208000003200 Adenoma Diseases 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 239000004677 Nylon Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- -1 antibodies Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000003292 diminished effect Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000011987 methylation Effects 0.000 description 4
- 238000007069 methylation reaction Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 108010067902 Peptide Library Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 201000010989 colorectal carcinoma Diseases 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002611 lead compounds Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- NJNAHFYVTBZQHU-LFFUDGMSSA-N (2s,5s,6r,10r,11s)-5-benzyl-10-heptyl-6-hydroxy-4,11-dimethyl-2-propan-2-yl-1,9-dioxa-4-azacyclododecane-3,8,12-trione Chemical compound CN1C(=O)[C@H](C(C)C)OC(=O)[C@@H](C)[C@@H](CCCCCCC)OC(=O)C[C@@H](O)[C@@H]1CC1=CC=CC=C1 NJNAHFYVTBZQHU-LFFUDGMSSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 102000004162 Claudin-1 Human genes 0.000 description 2
- 108090000600 Claudin-1 Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 102100023882 Endoribonuclease ZC3H12A Human genes 0.000 description 2
- 101710112715 Endoribonuclease ZC3H12A Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 101000648505 Homo sapiens Tumor necrosis factor receptor superfamily member 12A Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 238000009004 PCR Kit Methods 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- NJNAHFYVTBZQHU-UHFFFAOYSA-N hapalosin Natural products CN1C(=O)C(C(C)C)OC(=O)C(C)C(CCCCCCC)OC(=O)CC(O)C1CC1=CC=CC=C1 NJNAHFYVTBZQHU-UHFFFAOYSA-N 0.000 description 2
- 108010048227 hapalosin Proteins 0.000 description 2
- 238000007489 histopathology method Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010396 two-hybrid screening Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- JYLNVJYYQQXNEK-UHFFFAOYSA-N 3-amino-2-(4-chlorophenyl)-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(CN)C1=CC=C(Cl)C=C1 JYLNVJYYQQXNEK-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102100031065 Choline kinase alpha Human genes 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100441523 Homo sapiens CXCL5 gene Proteins 0.000 description 1
- 101000988362 Homo sapiens Calmodulin regulator protein PCP4 Proteins 0.000 description 1
- 101000777314 Homo sapiens Choline kinase alpha Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 101710102734 Proteinase inhibitor A Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012122 aqueous mounting media Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 238000011960 computer-aided design Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940116886 human interleukin-6 Drugs 0.000 description 1
- 230000032832 immune response to tumor cell Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- QGVYYLZOAMMKAH-UHFFFAOYSA-N pegnivacogin Chemical compound COCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(=O)(O)O QGVYYLZOAMMKAH-UHFFFAOYSA-N 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108700028325 pokeweed antiviral Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to an in-vitro method for detection of colorectal lesions.
- the method is based on the detection of the level of expression of polypeptides and nucleic acids comprising at least portions of nucleic acids or polypeptides, the expression of which is significantly altered in association with colorectal lesions.
- the method of the present invention may be used for early diagnosis, assessment of prognosis and monitoring of the disease course and for therapy of colorectal lesions and vaccination of individuals against said lesions.
- the most promising methods for early diagnosis of tumors are those involving molecular markers characteristic for tumor cells.
- Cancer is a quite heterogeneous disease. Multiple regulators of the cell growth can be involved in the genesis of cancer. These regulatory elements of the cell cycle can be either positive regulators, named oncogenes when mutated, so that a transformed state is reached, or negative regulators, named tumor suppressor genes. The number of factors known to be involved in the regulation of the cell cycle and potentially being candidates for the development of cancer exceeds 100 up to now and is still increasing.
- the molecules being involved in the emergence of the cancerous state of a cell can be used to discriminate between cancer cells and normal tissue.
- cancerous tissue can be detected by detecting molecules characteristic for the cancer cells. This turns out to be sophisticated due to the large number of molecules potentially being involved in causing cancer.
- the present invention provides compounds such as nucleic acids and polypeptides associated with colorectal cancer. According to the present invention theses sequences may be used as marker molecules that allow for comprehensive detection of colorectal lesions even at early stages.
- the present invention thus provides polypeptides and nucleic acids comprising at least portions of nucleic acids or polypeptides, the expression of which is significantly altered associated with colorectal lesions, that allow enhanced prognosis and diagnosis of diseases associated with abnormalities of the growth of cells.
- nucleic acids and/or polypeptides or combinations thereof may be used for therapy and/or vaccination of diseases associated with disorders of cell growth.
- compositions containing polypeptides and/or polynucleotides disclosed herein or combinations thereof optionally together with one or more other therapeutic or diagnostic agents and/or carrier or adjuvant substances.
- kits such as diagnostic kits or research kits comprising the polynucleotides or polypeptides disclosed herein or combinations thereof.
- the present invention is based on the inventors findings shown in the Examples 1- 4, that the level of expression of nucleic acid molecules or polypeptides selected from a group comprising ubiquitin-like protein FAT10 (Af123050); regenerating protein I beta (D16816); programmed cell death 9 PDCD9 (Af146192);androgen receptor associated protein 24 (Af052578); transcription factor ISGF-3 (M97936); guanylate binding protein isoform II GBP-2 (M55543); mitotic checkpoint BUB3 (Af047472); mitotic checkpoint component Bub3 (Af053304); apoptotic cysteine protease Mih1/TX isoform gamma (U28978); NRAS-related protein UNR (Ay049788); mammary tumor-associated protein INT6 mRNA (U94175); TBP-associated factor 170 TAFII170 (AJ001017); serine (or cysteine) proteinase inhibitor a!pha
- nucleic acid molecules in the respective grammatical forms throughout the present text shall refer to the nucleic acids or proteins obtainable for the following genes under the accession numbers given in brackets: ubiquitin-like protein FAT10 (Af 123050); regenerating protein I beta (D16816); programmed cell death 9 PDCD9 (Af146192);androgen receptor associated protein 24 (Af052578); transcription factor ISGF-3 (M97936); guanylate binding protein isoform II GBP-2 (M55543); mitotic checkpoint BUB3 (Af047472); mitotic checkpoint component Bub3 (Af053304); apoptotic cysteine protease Mih1/TX isoform gamma (U28978); NRAS-related protein UNR (Ay049788); mammary tumor-associated protein INT6 mRNA (U94175); TBP-associated factor 170 TAFII1
- the above mentioned terms shall refer to single molecules to groups of molecules or collectively to the listed molecules.
- the method according to the present invention is especially useful for early detection of disorders and for detection of disseminated tumor cells in the course of diagnosis of minimal residual disease.
- the present invention may be used for the diagnosis of tumors in samples such as tumor resections, biopsies or the like.
- the invention provides a method, that allows to build a strategy for the therapy of diseases according to their molecular properties.
- the level of said polypeptides or nucleic acids can be used as a molecular marker for assessment of prognosis, monitoring and the design of a strategy of tumor therapeutics.
- the present invention provides and makes use of compounds such as nucleic acids or polypeptides, the expression of which is significantly altered in association with colorectal lesions.
- Expression as used according to the present invention may comprise for example expression of proteins.
- the transcription to RNA and thus the level of mRNA may also be understood to be expression according to the present invention.
- the expression of a compound is said to be significantly altered according to the present invention, if the level of expression differs by more than 30%.
- the alteration of the expression may comprise for example elevated expression or reduced expression of said compound.
- Another aspect of the altered expression may be an alteration in a way, that the compound is expressed under non wild- type circumstances. This may comprise, that the compound is for example expressed in situations, that naturally suppress the expression, or is not expressed in situations, that naturally induce the expression of the compound.
- Alteration of the expression as used herein may also comprise an alteration in the transcription pattern of a gene.
- the alteration of the transcription pattern may comprise alternative splicing of the gene.
- the alterations in the transcription pattern may influence the polypeptides translated from the altered transcripts or may be restricted to untranslated regions.
- the alteration in the transcription pattern of a gene may comprise use of novel exons in the transcripts, deletions of exons in the transcripts or the variation in the ratios of different splicing variants in cells.
- alterations in transcriptional patterns of genes as used herein may comprise the production of nucleic acids such as e.g. mRNA, cDNA etc. containing additional stretches of nucleic acid sequences compared to wild type nucleic acids occurring in control tissues.
- nucleic acids produced by alternative splicing patterns may produce nucleic acids missing stretches of nucleic acid sequences present in wild type polynucleotides. The presence of additional stretches may occur simultaneously with the absence of original sequence-stretches in single transcripts.
- Alterations in the expression of genes as used in the context of the present invention may also comprise an alteration in the level of expression of splicing variants of genes. This may include increased or decreased expression of particular splicing variants as well as expression of variants not present in wild type tissue or the absence of expression of splicing variants present in wild type tissue.
- the alteration of the expression of the splicing variants may comprise the alteration of the ratios of different splicing variants in said tissue.
- An alteration is said to be in association with colorectal lesions as used in the context of the present invention, if said alteration in comparison to control tissue occurs in cells and/or tissues affected by said lesion.
- An expression pattern (overexpression or loss of expression or expression of altered sequences) of nucleic acids and polypeptides is associated with colorectal lesions as used herein, if the expression pattern is detectable in colorectal lesions and is not or not significantly detectable in normal control tissue.
- a nucleic acid or polypeptides is associated with colorectal lesions as used herein, if the expression of the nucleic acid or polypeptide is altered in association with colorectal lesions.
- Nucleic acids as used in the context of the present invention are preferably polynucleotides or fragments thereof.
- Polynucleotides may e.g. comprise at least 20 consecutive nucleotides, preferably at least 30 consecutive nucleotides and more preferably at least 45 consecutive nucleotides, that are identical, share sequence homology or encode for identical, or homologous polypeptides, compared to the polypeptides associated with the proliferative disorders disclosed herein.
- the nucleic acids according to the present invention may also be complementary to any of said polynucleotides.
- Polynucleotides may for example include single-stranded (sense or antisense) or double-stranded molecules, and may be DNA (genomic, cDNA or synthetic) or RNA. RNA molecules comprise as well hnRNA (containing introns) as mRNA (not containing introns). According to the present invention the polynucleotides may also be linked to any other molecules, such as support materials or detection marker molecules, and may, but need not, contain additional coding or non-coding sequences.
- the polynucleotides according to the present invention may be native sequences or variants thereof.
- the variants may contain one or more substitutions, additions, deletions and/or insertions such that the immunogenicity of the encoded polypeptide is not diminished, relative to the respective native proteins.
- the variants show preferably 70%, more preferably at least 80% and most preferably at least 90% of sequence identity to the native nucleic acid molecules used in the methods according to the present invention.
- Methods for determination of sequence similarity are known to those of skill in the art.
- One example for detecting the similarity of sequences can be carried out using the FastA and/or BlastN bioinformatics software accessible on the HUSAR server of the DKFZ Heidelberg.
- nucleic acids useful for performing the method of the present invention are all polynucleotides, which hybridise to probes specific for the sequences disclosed herein under stringent conditions.
- Stringent conditions applied for the hybridisation reaction are known to those of ordinary skill in the art and may be applied as described in Sambrook et al. Molecular cloning: A Laboratory Manual, 2 nd Edition, 1989.
- the present invention also makes use of polynucleotides, that due to the degeneracy of the genetic code encode the polypeptides natively encoded by the disclosed nucleic acids while not showing the percentage of sequence homology as described above within the nucleic acid sequence.
- Such nucleic acids might arise by changing the codons present in the disclosed sequences by degenerate codons and so preparing a synthetic nucleic acid.
- nucleotide sequences according to the present invention may be joined to a variety of other nucleic acid sequences using the known recombinant DNA techniques.
- the sequences may for example be cloned into any of a variety of cloning vectors, such as plasmids, phagemids, lambda phage derivatives and cosmids.
- vectors such as expression vectors, replication vectors, probe generation vectors and sequencing vectors may be joined with the sequences disclosed herein.
- Sequences of special interest, that could be cloned to the nucleic acids according to the present invention are for example non coding sequences and regulatory sequences including promoters, enhancers and terminators.
- polynucleotides may be formulated such, that they are able to enter mammalian cells and to be expressed in said cells. Such formulations are especially useful for therapeutic purposes.
- the expression of nucleic acid sequences in target cells may be achieved by any method known to those skilled in the art.
- the nucleic acids may for example be joined to elements that are apt to enable their expression in a host cell.
- Such elements may comprise promoters or enhancers, such as CMV-, SV40-, RSV-, metallothionein I- or polyhedrin-promotors respectively CMV- or SV40- enhancers.
- Possible methods for the expression are for example incorporation of the polynucleotides into a viral vector including adenovirus, adeno-associated virus, retrovirus, vaccinia virus or pox virus.
- Viral vectors for the purpose of expression of nucleic acids in mammalian host cells may comprise pcDNA3, pMSX, pKCR, pEFBOS, cDM8, pCEV4 etc.. These techniques are known to those skilled in the art.
- Other formulations for administration in therapeutic purposes include colloidal dispersion systems such as for example macromolecule complexes, microsp eres, beads, micelles and liposomes.
- Polypeptides as used in the present invention comprise at least an immunogenic portion of the proteins, that show significant alterations in their expression associated with colorectal lesions.
- the polypeptides may be of any length.
- Immunogenic portion as used above is a portion of a protein, that is recognized by a B-cell and/or T-cell surface antigen receptor.
- the immunogenic portions comprise at least 10 amino acid residues, more preferably at least 20 amino acid residues of the protein associated with a colorectal lesion.
- particular domains of the proteins such as for example transmembrane domains or N-terminal leader sequences have been deleted.
- the immunogenic portions according to the present invention react with antisera or specific antibodies in the same or nearly same intensity as the native full length proteins.
- the immunogenic portions are generally identified using the techniques well known in the art. Possible techniques are for example screening of the polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones.
- the polypeptides associated with proliferative disorders used in combinations according to the present invention comprise also variants of the native proteins. These variants may differ from the native protein in one or more alterations such as substitutions, deletions, additions and/or insertions.
- the immunoreactivity of the variants according to the present invention is not substantially diminished compared to the native proteins. In one embodiment of the invention the immunoreactivity is diminished less than 50% in another embodiment the immunoreactivity is diminished less than 20 % compared to the native polypeptides.
- variants may be deficient in one or more portions, such as for example N- terminal leader sequences, transmembrane domains or small N- and/or C-terminal sequences.
- the variants exhibit 70%, more preferably at least 90% and most preferably at least 95% identity to the polypeptides disclosed according to the present invention.
- the variants used according to the present invention are preferably conservative substitutions, so that the amino acids changed are substituted for amino acids with similar properties.
- the properties concerned may include polarity, charge, solubility, hydrophobicity, hydrophilicity and/or amphipathic nature of the amino acid residues.
- the variants useful for performing the methods disclosed herein may also comprise additional terminal leader sequences, linkers or sequences, which enable synthesis, purification or stability of the polypeptides in an easier or more comfortable way.
- the polypeptides may comprise fusion or chimeric polypeptides containing sequences disclosed herein.
- polypeptides and polynucleotides according to the present invention are isolated. This means that the molecules are removed from their original environment. Naturally occurring proteins are isolated if they are separated from some or all of the materials, which coexist in the natural environment. Polynucleotides are isolated for example if they are cloned into vectors.
- the present invention makes use of agents such as antibodies and antigen-binding fragments, that specifically bind to the proteins associated with a colorectal lesion.
- the antibody or antigen-binding agent is said to react specifically, if it reacts at a detectable level with a protein disclosed herein, and does not significantly react with other proteins.
- the antibodies according to the present invention may be monoclonal or polyclonal antibodies.
- Other molecules capable of binding specifically may be for example antigen-binding fragments of antibodies such as Fab fragments, RNA molecules or polypeptides.
- binding agents may be used isolated or in combination. By means of combination it is possible to achieve a higher degree of sensitivity.
- the antibodies useful for the methods according to the present invention may comprise further binding sites for either therapeutic agents or other polypeptides or may be coupled to said therapeutic agents or polypeptides.
- Therapeutic agents may comprise drugs, toxins, radio-nuclides and derivatives thereof.
- the agents may be coupled to the binding agents either directly or indirectly for example by a linker or carrier group.
- the linker group may for example function in order to enable the coupling reaction between binding agent and therapeutic or other agent or the linker may act as a spacer between the distinct parts of the fusion molecule.
- the linker may also be cleavable under certain circumstances, so as to release the bound agent under said conditions.
- the therapeutic agents may be covalently coupled to carrier groups directly or via a linker group.
- the agent may also be non-covalently coupled to the carrier.
- Carriers that can be used according to the present invention are for example albumins, polypeptides, polysaccharides or liposomes.
- the antibody used according to the present invention may be coupled to one or more agents.
- the multiple agents coupled to one antibody may be all of the same species or may be several different agents bound to one antibody.
- Another aspect of the present invention is a pharmaceutical compositon for use in the treatment of disorders associated with abnormal cell proliferation.
- the polypeptides, polynucleotides and binding agents (esp. antibodies) according to the present invention may be incorporated into pharmaceutical or immunogenic compositions.
- compositions may be administered by any suitable way known to those of skill in the art.
- the administration may for example comprise injection, such as e.g., intracutaneous, 5 intramuscular, intravenous or subcutaneous injection, intranasal administration for example by aspiration or oral administration.
- a suitable dosage to ensure the pharmaceutical benefit of the treatment should be chosen according the parameters, such as age, sex, body weight etc. of the patient, known to those of skill in the art.
- the pharmaceutical compositions comprise said compounds and a physiologically acceptable J O carrier.
- the type of carrier to be employed in the pharmaceutical compositions of this invention will vary depending on the mode of administration.
- the carrier preferably comprises water, saline, alcohol, a lipid, a wax and/or a buffer.
- any of the above carriers or a solid carrier such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and/or magnesium is carbonate, may be employed.
- Biodegradable microspheres e.g. polylactic glycolide
- Suitable biodegradable microspheres are disclosed, for example, in U.S. Pat. Nos. 4,897,268 and 5,075,109.
- a pharmaceutical composition or vaccine may for example contain DNA, that codes for one or more polypeptides according to the present invention.
- the DNA may be administered in a way that allows 20 the polypeptides to be generated in situ. Suitable expression systems are known to those skilled in the art.
- the nucleic acids may be for example anti-sense constructs.
- Pharmaceutical compositions may also comprise nucleic acid molecules expressible in a mammalian or human host system comprising a viral or other expression system for example an adenoviral vector system.
- the nucleic acid may also be administered as a naked nucleic acid.
- appropriate physical delivery systems which enhance the uptake of nucleic acid may be employed, such as coating the nucleic acid onto biodegradable beads, which are efficiently transported into the cells.
- Administration of naked nucleic acids may for example be useful for the purpose of transient expression within a host or host cell.
- the pharmaceutical compositions may comprise one or more polypeptides.
- the polypeptides incorporated into pharmaceutical compositions may be the inventive colorectal lesion associated polypeptide in combination with one or more other known polypeptides such as for example enzymes, antibodies, regulatory factors, such as e.g. cyclins, cyclin-dependent kinases or CKIs, or toxins.
- Polypeptides of the present invention or fragments thereof, that comprise an immunogenic portion of a inventive colorectal lesion associated protein may be used in immunogenic compositions, wherein 5 the polypeptide e.g. stimulates the patient's own immune response to tumor cells.
- a patient may be afflicted with disease, or may be free of detectable disease.
- the compounds disclosed herein may be used to treat cancer or to inhibit the development of cancer.
- the compounds may be administered either prior to or following a conventional treatment of tumors such as surgical removal of primary tumors, treatment by administration of radiotherapy, conventional chemotherapeutic o methods or any other mode of treatment of the respective cancer or its precursors.
- Immunogenic compositions such as vaccines may comprise one or more polypeptides and a nonspecific immune-response enhancer, wherein the non-specific immune response enhancer is capable of eliciting or enhancing an immune response to an exogenous antigen.
- a suitable immune-response enhancer may be employed in the vaccines of this invention.
- an s adjuvant may be included.
- Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminium hydroxide or mineral oil, and a non-specific stimulator of immune response, such as lipid A, Bordetella pertussis or Mycobacterium tuberculosis.
- adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.) and Merck Adjuvant 65 (Merck and Company, Inc., o Rahway, N.J.).
- compositions and vaccines may also contain other epitopes of tumor antigens, either incorporated into a fusion protein as described above (i.e., a single polypeptide that contains multiple epitopes) or present within a separate polypeptide.
- a vital aspect of the present invention is the diagnosis of colorectal lesions.
- the detection of 5 diseases may be carried out for example by detecting the level of expression of one or more molecular markers in biological samples.
- Molecular markers as used according to the present invention are molecules associated with colorectal lesions. Such molecules may comprise polynucleotides or polypeptides. Polypeptides may comprise the inventive colorectal lesion associated polypeptides or fragments thereof or proteins or fragments thereof interacting with the 0 inventive colorectal lesion associated polypeptides.
- Nucleic acids for use as molecular markers may comprise nucleic acids coding for the inventive colorectal lesion associated polypeptides or for proteins interacting with the inventive colorectal lesion associated polypeptides, such as for example DNA, cDNA or RNA.
- the polynucleotides or polypeptides disclosed to be useful for the diagnostic methods of this invention are the molecular markers to be detected.
- Colorectal lesions according to the present invention comprise conditions of the colorectal tract characterized by abnormal growth properties of cells or tissues compared to the growth properties of normal control cells or tissues.
- the growth of the cells or tissues may be for example abnormally accelerated, decelerated or may be regulated abnormally.
- Abnormal regulation as used above may comprise any form of presence or absence of non wild-type responses of the cells or tissues to naturally occurring growth regulating influences.
- the abnormalities in growth of the cells or tissues may be for example neoplastic or hyperplastic.
- the colorectal lesions are cancers or precancerous conditions of the colon.
- Colorectal lesions as used in the context of the present invention are any lesions of the colon and the rectum.
- the colorectal lesions according to the present invention comprise lesions of the colorectal tract of any anatomical location therein. The lesions thus may be located in the colon ascendens, the colon transversum, the colon descendens, the colon sigmoidum or the rectum.
- the lesions according to the present invention comprise conditions characterized by abnormal growth properties of cells or tissues compared to the growth properties of normal control cells or tissues. The growth of the cells or tissues may be for example abnormally accelerated or may be regulated abnormally. Abnormal regulation as used above may comprise any form of presence or absence of non wild-type responses of the cells or tissues to naturally occuring growth regulating influences.
- the abnormalities in growth of the cells or tissues may be for example neoplastic or hyperplastic.
- the colorectal lesions are cancers or precancerours conditions of the colon and/or rectum.
- the colorectal lesions are tumors.
- the tumors are cancers or precancerours conditions of the colorectal tract.
- a sample according to the method of the present invention is any sample, that may contain cells, tissues or body liquids. Furthermore any sample potentially containing the marker molecules to be detected may be a sample according to the present invention. Such samples are e.g. blood, plasma, serum, secretions, such as gastrointestinal secretions or other glandular secretions, smears, washes, stool, bile, cell- and tissue-samples or biopsies.
- samples are e.g. blood, plasma, serum, secretions, such as gastrointestinal secretions or other glandular secretions, smears, washes, stool, bile, cell- and tissue-samples or biopsies.
- Biopsies as used in the context of the present invention may comprise e.g. resection samples of tumors, tissue samples prepared by endoscopic means or needle biopsies of organs. Furthermore any sample potentially containing the marker molecules to be detected may be a sample according to the present invention.
- the method for detection of the level of the polynucleotides or polypetides according to the present invention is any method, which is suited to detect very small amounts of specific biologically active molecules in samples.
- the detection reaction according to the present invention may be for example a detection either on the level of nucleic acids or on the level of polypeptides.
- the detection may either be a detection of the level of polypeptides or nucleic acids in cells in total or in cell lysats or a detection of the level of polypeptides or nucleic acids in distinct subcellular regions.
- the methods for determining the subcellular distribution of compounds are known to those of skill in the art.
- the detection method may comprise the detection of methylation of nucleic acid molecules in samples.
- Applicable formats for the detection reaction according to the present invention may be blotting techniques, such as Western-Blot, Southern-blot, Northern-blot.
- the blotting techniques are known to those of ordinary skill in the art and may be performed for example as electro-blots, semidry-biots, vacuum-blots or dot-blots.
- immunological methods for detection of molecules may be applied, such as for example immunoprecipitation or immunological assays, such as ELISA, RIA, lateral flow assays etc..
- Methods for detection of methylation of nucleic acids are known to those of skill in the art and may comprise for example methods employing chemical pre-treatment of nucleic acids with e.g. sodium bisulphite, permanganate or hydrazine, and subsequent detection of the modification by means of specific restriction endonucleases or by means of specific probes e.g. in the course of an amplification reaction.
- the detection of methylation may furthermore be performed using methylation specific restriction endonucleases.
- the detection of the level of marker molecules is carried out by detection of the level of nucleic acids coding for the marker molecules or fragments thereof present in the sample.
- the means for detection of nucleic acid molecules are known to those skilled in the art.
- the procedure for the detection of nucleic acids can for example be carried out by a binding reaction of the molecule to be detected to complementary nucleic acid probes, proteins with binding specificity for the nucleic acids or any other entities specifically recognizing and binding to said nucleic acids. This method can be performed as well in vitro as directly in-situ for example in the course of a detecting staining reaction.
- Another way of detecting the marker molecules in a sample on the level of nucleic acids performed in the method according to the present invention is an amplification reaction of nucleic acids, which can be carried out in a semi-quantitative or quantitative manner such as for example PCR, LCR or NASBA.
- real time RT PCR may be used to quantify the level of marker RNA in samples of colorectal lesions.
- the detection of the level of marker molecules is carried out by determining the level of expression of a protein. The determination of the marker molecules on the protein level may for example be carried out in a reaction comprising a binding agent specific for the detection of the marker molecules.
- binding agents may comprise for example antibodies and antigen-binding fragments, bifunctional hybrid antibodies, peptidomimetics containing minimal antigen-binding epitopes etc.
- the binding agents may be used in many different detection techniques for example in western-blot, ELISA, lateral flow assay, latex-agglutination, immunochromatographic strips or immuno-precipitation.
- binding agent based detection may be carried out as well in vitro as directly in situ for example in the course of an immuno- cytochemical staining reaction. Any other method suitable for determining the amount of particular polypeptides in solutions of biological samples can be used according to the present invention.
- the detection of a series of marker molecules is carried out on the level of polypeptides and simultaneously the detection of a further series of marker molecules and/or of all or some of the same marker molecules is carried out on the level of nucleic acids.
- the expression level of markers is significantly elevated compared to a non tumorous test sample. In this case the marker is overexpressed in the sample. In another embodiment of the present invention the level of the marker is lowered compared to a non tumorous test sample. In a third embodiment there is no detectable expression of the marker at all in the test sample unlike in a control sample. In yet another embodiment there is detectable level of non wild-type marker molecules.
- Non wild-type marker molecules may comprise any marker molecules that deviate in sequence or structure from the structure or sequence, that is functional in wild type tissue not affected by a cell proliferative disease. Wild type sequences or structures are the sequences or structures predominantly present in normal cells or tissues.
- the detection of the level of molecular markers according to the present invention may be the detection of the level of single marker molecules in separated reaction mixtures as well as the detection of a combination of markers simultaneously.
- the combination may comprise any of the molecular markers disclosed herein. Furthermore there are possible combinations of the markers disclosed with other molecular markers known in the art.
- the detection may be carried out in solution or using reagents fixed to a solid phase.
- the detection of one or more molecular markers may be performed in a single reaction mixture or in two or separate reaction mixtures.
- the detection reactions for several marker molecules may for example be performed simultaneously in multi-well reaction vessels.
- the markers disclosed herein may be detected using reagents that specifically recognise these molecules. Simultaneously one or more further markers may be detected using reagents, that specifically recognize them.
- the detection reaction for each single marker may comprise one or more reactions with detecting agents either recognizing the initial marker molecules or preferably recognizing molecules used to recognize other molecules. Such reaction may e.g. comprise the use of primary and secondary and further antibodies.
- the detection reaction further may comprise a reporter reaction indicating the level of the inventive polypeptides.
- the reporter reaction may be for example a reaction producing a coloured compound, a bioluminescence reaction, a fluorescence reaction, generally a radiation emitting reaction etc..
- the reporter reaction may be for example a reaction producing a coloured compound.
- the reporter substances correlated to the particular markers develop different colours.
- the reporter reactions may produce fluorescent dyes with differing wavelength characteristics.
- the reporter reaction may comprise light emitting reactions with different wavelength characteristics for the reporter substances specific for either marker to be detected.
- the reporter reaction may comprise the emission of radioactive irradiation and additional methods for visualizing or quantifying the irradiation.
- the different marker molecules may be recognized by agents, that bear radio-nuclides emitting irradiation with different energetic properties, so that the signals referring to marker molecules could be distinguished.
- the detection of tissues expressing marker gene products is carried out in form of molecular imaging procedures.
- the respective procedures are known to those of ordinary skill in the art.
- Imaging methods for use in the context of the present invention may for example comprise MRI, SPECT, PET and other methods suitable for in vivo imaging.
- the method may be based on the enzymatic conversion of inert or labelled compounds to molecules detectable in the course of molecular imaging methods by the marker molecules.
- the molecular imaging method may be based on the use of compounds carrying a suitable label for in vivo molecular imaging, such as radio isotopes, metal ions etc., specifically binding to marker molecules in vivo.
- these compounds are non-toxic compounds and may be eliminated from the circulation of organisms, such as humans, in a time span, that allows for performing the detection of label accumulated in tumor tissue overexpressing the respective marker gene.
- compounds are used for molecular imaging, for which clearance from the circulation is not relevant for performing the molecular imaging reaction. This may be for example due to low background produced by the circulating molecules etc.
- the compounds for use in molecular imaging methods are administered in pharmaceutical acceptable form in compositions that may additionally comprise any other suitable substances, such as e.g. other diagnostically useful substances, therapeutically useful substances, carrier substances or the like.
- the marker molecules disclosed according to the present invention may be used for diagnosis, monitoring of the disease course and prognosis in colorectal lesions.
- Diagnosis of colorectal lesions may for example comprise the detection of cells or tissues affected by abnormal growth.
- diagnosis means the primary detection of a disease in an organism or sample.
- the method for diagnosis of the colorectal lesion may be applied in routine screening tests for preventive aspects in order to detect said disease at an early stage of the onset of the disorder.
- the diagnostic method may be used to determine the minimal residual disease of a tumor after primary therapy.
- the method of the invention may be applied to determine cells in body samples displaying abnormal expression of marker molecules according to the present invention, characteristic for colorectal lesions. Thus a spread of affected cells may be detected in body liquids.
- the determination of disseminated tumor cells according to the present invention may be performed before, during or even after primary treatment of colorectal lesions and may for example be performed for purposes of staging.
- the detection of the compounds disclosed herein may comprise the detection of spread tumor cell to lymph nodes.
- the methods disclosed herein may be used for the detection and identification of metastases.
- the method may be applied either for detection of metastases in body tissues or organs by the detection methods described herein, or the metastases may be diagnoses with respect to prognosis and prediction of disease course.
- Monitoring of the disease course may comprise determining the levels of a set of marker molecules at different time points, comparing the levels at the different time points and assessing a diagnosis about the progression of the disease over the covered period of time.
- Monitoring may enable for assessment of prognosis and/or for design of an adequate therapy for a particular patient.
- Prognosis of the disease course of a colorectal lesion may comprise determining the level of expression of one or more marker molecules, comparing the levels with data from subsequent studies in a database and prognosticating the disease course from said comparison.
- the method may comprise the detection of the levels of a set of marker molecules, the distinct levels of which may characterize distinct stages in the course of the disease.
- the combination of the levels of a combination of markers may be an indicator for the prognosis of the further disease course and may build the basis for design of an adequate therapy.
- kits for use in e.g. research or diagnostic methods.
- Such kits may contain two or more components for performing a scientific or diagnostic assay.
- Components may be compounds, reagents, containers and/or equipment.
- One component may be an antibody or fragment thereof that specifically binds to a polypeptide associated with colorectal lesions.
- the kit may contain reagents, buffers or others known in the art as necessary for performing the diagnostic assay.
- the research kit or diagnostic kit may contain nucleotide probes or primers for the detection of DNA or RNA.
- Such a kit could contain appropriate additional reagents and buffers known in the art.
- a kit according to present invention comprises:
- the reagents and buffers commonly used for carrying out the detection reaction such as buffers, detection-markers, carrier substances and others
- the reagent for the detection of the marker includes any agent capable of binding to the marker molecule.
- Such reagents may include proteins, polypeptides, peptidomimetics, nucleic acids, glycoproteins, proteoglycans, polysaccharids, anticalins or lipids.
- the sample for carrying out a positive control may comprise for example nucleic acids in applicable form, such as solution or salt, peptides in applicable form, tissue section samples or positive cells expressing the molecules associated with colorectal lesions.
- the detection of the marker molecules is carried out on the level of polypeptides.
- the binding agents may be for example antibodies specific for the marker molecules or fragments thereof.
- the detection of the marker molecule is carried out on the nucleic acid level.
- the reagents for the detection may be for example nucleic acid probes or primers complementary to said marker molecule nucleic acids.
- Another aspect of the present invention is to provide a method for therapy and/or vaccination.
- a therapy of cell proliferative disorders can be carried out using the inventive colorectal lesion associated polypeptides and/or polynucleotides.
- the therapy may be for example immunotherapy or somatic gene therapy.
- the inventive colorectal lesion associated polypeptides and/or polynucleotides may according to the present invention be used for vaccination against cell proliferative disorders.
- Vaccination according to the present invention may comprise administering an immunogenic compound to an individual for the purpose of stimulating an immune response directed against said immunogenic compound and thus immunizing said individual against said immunogenic compound.
- Stimulating an immune response may comprise inducing the production of antibodies against said compound as well as stimulating cytotoxic T-cells.
- the polypeptides, nucleic acids and binding agents according to the present invention may be administered in a physiological acceptable form.
- the composition to be administered to individuals may comprise one or more antigenic components, physiologically acceptable carrier substances or buffer solutions, immunostimulants and/or adjuvants.
- Adjuvants may comprise for example Freund's incomplete adjuvant or Freund's complete adjuvant or other adjuvants known to those of skill in the art.
- the composition may be administered in any applicable way such as e.g. intravenous, subcutaneous, intramuscular etc..
- the dosage of the composition depends on the particular case and purpose of the vaccination. It has to be adapted to parameters by the individual treated such as age, weight, sex etc.. Furthermore the type of the immune response to be elicited has to be taken into account. In general it may be preferable if an individual receives 100 ⁇ g - 1 g of a polypeptide according to the present invention or 10 6 - 10 12 MOI of a recombinant nucleic acid, containing a nucleic acid according to the present invention in a form that may be expressed in situ.
- Individuals for the purpose of vaccination may be any organisms containing the inventive colorectal lesion associated polypeptides and/or . polynucleotides and being able to get affected by cell proliferative disorders.
- Vaccination of individuals may be favourable e.g. in the case of altered, non wild-type sequences or structure of marker molecules associated with cell proliferative disorders.
- Polypeptides disclosed herein may also be employed in adoptive immunotherapy for the treatment of cancer.
- Adoptive immunotherapy may be broadly classified into either active or passive immunotherapy.
- active immunotherapy treatment relies on the in vivo stimulation of the endogenous host immune system to react against tumors with the administration of immune response-modifying agents (for example, tumor vaccines, bacterial adjuvants, and/or cytokines).
- immune response-modifying agents for example, tumor vaccines, bacterial adjuvants, and/or cytokines.
- effector cells include T lymphocytes (for example, CD8+ cytotoxic T-lymphocyte, CD4+ T-helper, tumor-infiltrating lymphocytes), killer cells (such as Natural Killer cells, lymphokine-activated killer cells), B cells, or antigen presenting cells (such as dendritic cells and macrophages) expressing the disclosed antigens.
- T lymphocytes for example, CD8+ cytotoxic T-lymphocyte, CD4+ T-helper, tumor-infiltrating lymphocytes
- killer cells such as Natural Killer cells, lymphokine-activated killer cells
- B cells or antigen presenting cells (such as dendritic cells and macrophages) expressing the disclosed antigens.
- antigen presenting cells such as dendritic cells and macrophages
- the predominant method of procuring adequate numbers of T-cells for adoptive immunotherapy is to grow immune T-cells in vitro.
- Culture conditions for expanding single antigen-specific T-cells to several billion in number with retention of antigen recognition in vivo are well known in the art.
- These in vitro culture conditions typically utilize intermittent stimulation with antigen, often in the presence of cytokines, such as IL-2, and non-dividing feeder cells.
- cytokines such as IL-2
- the immunoreactive polypeptides described herein may be used to rapidly expand antigen-specific T cell cultures in order to generate sufficient number of cells for immunotherapy.
- antigen-presenting cells such as dendritic, macrophage or B-cells
- antigen presenting cells may be transfected with a nucleic acid sequence, wherein said sequence contains a promoter region appropriate for increasing expression, and can be expressed as part of a recombinant virus or other expression system.
- the cultured T-cells must be able to grow and distribute widely and to survive long term in vivo.
- the polypeptides disclosed herein may also be employed to generate and/or isolate tumor-reactive T-cells, which can then be administered to the patient.
- antigen-specific T-cell lines may be generated by in vivo immunization with short peptides corresponding to immunogenic portions of the disclosed polypeptides.
- the resulting antigen specific CD8 + CTL clones may be isolated from the patient, expanded using standard tissue culture techniques, and returned to the patient.
- peptides corresponding to immunogenic portions of the polypeptides of the invention may be employed to generate tumor reactive T-cell subsets by selective in vitro stimulation and expansion of autologous T-cells to provide antigen-specific T-cells which may be subsequently transferred to the patient as described, for example, by Chang et al. (Crit. Rev. Oncol. Hematol., 22(3), 213, 1996).
- Cells of the immune system such as T-cells, may be isolated from the peripheral blood of a patient, using a commercially available cell separation system, such as CellPro Incorporated's (Bothell, Wash.) CEPRATE.TM. system (see U.S. Pat. No. 5,240,856; U.S. Pat. No.
- the separated cells are stimulated with one or more of the immunoreactive polypeptides contained within a delivery vehicle, such as a microsphere, to provide antigen-specific T-cells.
- a delivery vehicle such as a microsphere
- the population of tumor antigen-specific T-cells is then expanded using standard techniques and the cells are administered back to the patient.
- T-cell and/or antibody receptors specific for the polypeptides can be cloned, expanded, and transferred into other vectors or effector cells for use in adoptive immunotherapy.
- syngeneic or autologous dendritic cells may be pulsed with peptides corresponding to at least an immunogenic portion of a polypeptide disclosed herein.
- the resulting antigen-specific dendritic cells may either be transferred into a patient, or employed to stimulate T- cells to provide antigen-specific T-cells, which may, in turn, be administered to a patient.
- the use of peptide-pulsed dendritic cells to generate antigen-specific T-cells and the subsequent use of such antigen-specific T-cells to eradicate tumors in a murine model has been demonstrated by Cheever et al, Immunological Reviews, 157:177, 1997.
- vectors expressing the disclosed nucleic acids may be introduced into stem cells taken from the patient and clonally propagated in vitro for autologous transplant back into the same patient.
- Monoclonal antibodies of the present invention may also be used as therapeutic compounds in order to diminish or eliminate tumors.
- the antibodies may be used on their own (for instance, to inhibit metastases) or coupled to One or more therapeutic agents.
- Suitable agents in this regard include radio nuclides, differentiation inducers, drugs, toxins, and derivatives thereof.
- Radio nuclides include 90Y, 1231, 1251, 1311, 186Re, 188Re, 211 At, and 212BL
- Drugs include methotrexate, and pyrimidine and purine analogues.
- Differentiation inducers include phorbol esters and butyric acid.
- Toxins include ricin, abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas exotoxin, Shigella toxin, and pokeweed antiviral protein.
- the therapy of colorectal lesions may comprise the administration of antisense constructs or ribozymes.
- the methods for administration of ribozymes or antisense constructs are known to those of skill in the art.
- the administration may take place as administration of naked nucleic acids or as administration of nucleic acids that are suited for expression of the relevant active products in situ.
- the treatment of disorders may e.g. comprise the administration of binding agents directed against the inventive colorectal lesion associated molecules. These binding s agents may for example be coupled to other compounds such as toxins, enzymes, radio-isotopes etc.
- the treatment of disorders may comprise the administration of binding agents directed against the polypeptides.
- binding agents may for example be coupled to other compounds such as toxins, enzymes, radio-isotopes etc.
- therapy of disorders associated with abnormal expression of the presented polypeptides may comprise the administration of antagonists or agonists of the polypeptides, of binding partners of the polypeptides of inhibitors or enhancers of the expression of the polypeptides disclosed herein or of drugs identifiable by assays involving the measurement of the activity of the polypeptides of the present invention.
- the methods for identifying these substances s are known to those of skill in the art.
- An example for a method for identifying a binding partner of an inventive colorectal lesion associated polypeptide e.g. the GPCR disclosed herein characterized by the Sequence given in Figure 9) (or related polypeptide) and/or polynucleotide may comprise:
- inventive colorectal lesion associated polypeptide may be used to screen for proteins or other compounds that bind to the inventive colorectal lesion associated polypeptides or for proteins or other compounds to which the inventive colorectal lesion associated protein (e.g. the GPCR) binds. 5
- the binding of the inventive colorectal lesion associated polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the inventive colorectal lesion associated polypeptide or the molecule bound.
- examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.
- the molecule is closely related to the natural ligand of the inventive colorectal lesion 0 associated protein, a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic; see, e.g., Coligan, Current Protocols in Immunology 1(2) (1991); Chapter 5.
- the molecule can be closely related to a natural receptor to which the inventive colorectal lesion associated polypeptide might bind, or at least, a fragment of the receptor capable of being bound by the inventive colorectal lesion associated polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.
- the screening for these molecules involves producing appropriate cells which express the inventive colorectal lesion associated polypeptide (in certain embodiments of the invention the GPCR), either as a secreted protein or on the cell membrane.
- Cells include e.g. cells from mammals, yeast, Drosophila, or E. coli.
- Cells expressing the inventive colorectal lesion associated polypeptides (or cells containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of the inventive colorectal lesion associated protein.
- the assay may simply test binding of a candidate compound to the inventive colorectal lesion associated polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labelled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the inventive colorectal lesion associated polypeptide.
- the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures.
- the assay may also simply comprise the steps of mixing a candidate compound with a solution containing the inventive colorectal lesion associated polypeptide, measuring the inventive colorectal lesion associated polypeptide/molecule activity or binding, and comparing the inventive colorectal lesion associated polypeptide activity or binding to a standard.
- an ELISA assay can measure the inventive colorectal lesion associated protein level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody.
- the antibody can measure the inventive colorectal lesion associated polypeptide level or activity by either binding, directly or indirectly, to the inventive colorectal lesion associated polypeptide or by competing with the inventive colorectal lesion associated polypeptide for a substrate. All of these above assays can be used as diagnostic or prognostic markers.
- the molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., elimination of a epthelial tumor or stop of progression of tumor growth) by activating or inhibiting the inventive colorectal lesion associated protein molecule.
- the assays can discover agents which may inhibit or enhance the production of the inventive colorectal lesion associated polypeptide from suitably manipulated cells or tissues.
- the invention includes a method of identifying compounds for use in treatment of disorders characterized by abnormal cell proliferation which bind to a the inventive colorectal lesion associated polypeptides comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention (the inventive colorectal lesion associated GPCR) ; and (b) determining if binding has occurred.
- the invention includes a method of identifying activators/agonists or inhibitors/antagonists of the inventive colorectal lesion associated polypeptides for use in treatment of disorders characterized by abnormal cell proliferation comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention; b) assaying a biological activity, and (c) determining if a biological activity of the polypeptide of the invention (e.g. receptor activity) has been altered.
- a biological activity of the polypeptide of the invention e.g. receptor activity
- the present invention relates to method of identifying and obtaining a drug candidate for therapy of a disorder associated with abnormal cell proliferation comprising the steps of
- the drug candidate may be a single compound or a plurality of compounds.
- the term "plurality of compounds" in a method of the invention is to be understood as a plurality of substances which may or may not be identical.
- Said compound or plurality of compounds may be chemically synthesized or microbiologically produced and/or comprised in, for example, samples, e.g., cell extracts from, e.g., plants, animals or microorganisms.
- said compound(s) may be known in the art but hitherto not known to be capable of suppressing or activating the inventive colorectal lesion associated polypeptide.
- the reaction mixture may be a cell free extract or may comprise a cell or tissue culture. Suitable set ups for the method of the invention are known to the person skilled in the art and are, for example, generally described in Alberts et al., Molecular Biology of the Cell, third edition (1994) and in the appended examples.
- the plurality of compounds may be, e.g., added to the reaction mixture, culture medium, injected into a cell or otherwise applied to the transgenic animal.
- the cell or tissue that may be employed in the method of the invention preferably is a host cell, mammalian cell or non-human transgenic animal of the invention described in the embodiments hereinbefore.
- a sample containing a compound or a plurality of compounds is identified in the method of the invention, then it is either possible to isolate the compound from the original sample identified as containing the compound capable of suppressing or activating the inventive colorectal lesion associated polypeptide, or one can further subdivide the original sample, for example, if it consists of a plurality of different compounds, so as to reduce the number of different substances per sample and repeat the method with the subdivisions of the original sample.
- the steps described above can be performed several times, preferably until the sample identified according to the method of the invention only comprises a limited number of or only one substance(s).
- said sample comprises substances of similar chemical and/or physical properties, and most preferably said substances are identical.
- phage- display method in which randomized peptides are displayed from phage and screened by affinity chromatography to an immobilized receptor; see, e.g., WO 91/17271 , WO 92/01047, US-A- 5,223,409.
- combinatorial libraries of polymers immobilized on a chip are synthesized using photolithography; see, e.g., US-A-5,143,854, WO 90/15070 and WO 92/10092.
- the immobilized polymers are contacted with a labeled receptor and scanned for label to identify polymers binding to the receptor.
- WO 98/25146 described further methods for screening libraries of complexes for compounds having a desired property, especially, the capacity to agonize, bind to, or antagonize a polypeptide or its cellular receptor.
- the complexes in such libraries comprise a compound under test, a tag recording at least one step in synthesis of the compound, and a tether susceptible to modification by a reporter molecule. Modification of the tether is used to signify that a complex contains a compound having a desired property.
- the tag can be decoded to reveal at least one step in the synthesis of such a compound.
- Mimetic analogues of the polypeptide of the invention can be generated by, for example, substituting the amino acids that are expected to be essential for the biological activity with, e.g., stereoisomers, i.e. D-amino acids; see e.g., Tsukida, J. Med. Chem. 40 (1997), 3534-3541.
- pro-mimetic components can be incorporated into a peptide to re-establish at least some of the conformational properties that may have been lost upon removal of part of the original polypeptide; see, e.g., Nachman, Regul. Pept. 57 (1995), 359-370.
- inventive colorectal lesion associated polypeptide can be used to identify synthetic chemical peptide mimetics that bind to or can function as a ligand, substrate, binding partner or the receptor of the polypeptide of the invention as effectively as does the natural polypeptide; see, e.g., Engleman, J. Clin. Invest. 99 (1997), 2284- 2292.
- folding simulations and computer redesign of structural motifs of the polypeptide of the invention can be performed using appropriate computer programs (Olszewski, Proteins 25 (1996), 286-299; Hoffman, Comput. Appl. Biosci. 11 (1995), 675-679).
- Computer modelling of protein folding can be used for the conformational and energetic analysis of detailed peptide and protein s models (Monge, J. Mol. Biol. 247 (1995), 995-1012; Renouf, Adv. Exp. Med. Biol. 376 (1995), 37- 45).
- the appropriate programs can be used for the identification of interactive sites of the inventive colorectal lesion associated polypeptide and its possible ligand or other interacting proteins by computer assistant searches for complementary peptide sequences (Fassina, Immunomethods 5 (1994), 1 14-120. Further appropriate computer systems for the design of protein o and peptides are described in the prior art, for example in Berry, Biochem. Soc. Trans. 22 (1994), 1033-1036; Wodak, Ann. N. Y. Acad. Sci. 501 (1987), 1-13; Pabo, Biochemistry 25 (1986), 5987- 5991.
- results obtained from the above-described computer analysis can be used for, e.g., the preparation of peptide mimetics of the protein of the invention or fragments thereof.
- Such pseudopeptide analogues of the natural amino acid sequence of the protein may very efficiently s mimic the parent protein (Benkirane, J. Biol. Chem. 271 (1996), 33218-33224).
- incorporation of easily available achiral *-amino acid residues into a protein of the invention or a fragment thereof results in the substitution of amide bonds by polymethylene units of an aliphatic chain, thereby providing a convenient strategy for constructing a peptide mimetic (Banerjee, Biopolymers 39 (1996), 769-777).
- polypeptide of the invention can be used for the design of peptide mimetic inhibitors of the biological activity of the polypeptide of the invention (Rose, Biochemistry 35 (1996), 12933-12944; Rutenber, Bioorg. Med. Chem. 4 (1996), 1545-1558).
- Activators may comprise, for example, proteins that bind to the mRNA of a gene encoding a the inventive colorectal lesion associated polypeptide, thereby stabilizing the native conformation of the mRNA and facilitating transcription and/or translation, e.g., in like manner as Tat protein acts on HIV- RNA.
- methods are described in the literature for identifying nucleic acid molecules such as an RNA fragment that mimics the structure of a defined or undefined target RNA molecule to which a compound binds inside of a cell resulting in retardation of cell growth or cell death; see, e.g., WO 98/18947 and references cited therein.
- nucleic acid molecules can be used for identifying unknown compounds of pharmaceutical and/or agricultural interest, and for identifying unknown RNA targets for use in treating a disease.
- These methods and compositions can be used in screening for novel antibiotics, bacteriostatics, or modifications thereof or for identifying compounds useful to alter expression levels of proteins encoded by a nucleic acid molecule.
- the conformational structure of the RNA fragment which mimics the binding site can be employed in rational drug design to modify known antibiotics to make them bind more avidly to the target.
- One such methodology is nuclear magnetic resonance (NMR), which is useful to identify drug and RNA conformational structures.
- NMR nuclear magnetic resonance
- Still other methods are, for example, the drug design methods as described in WO 95/35367, US-A-5,322,933, where the crystal structure of the RNA fragment can be deduced and computer programs are utilized to design novel binding compounds which can act as antibiotics.
- nucleic acid molecules and encoded polypeptides of the present invention may also be used to design and/or identify molecules which are capable of activating the wild-type, i.e. "colorectal lesion associated polypeptide” or "anti- colorectal lesion associated polypeptide” function of a the inventive colorectal lesion associated polypeptide.
- the compounds which can be tested and identified according to a method of the invention may be expression libraries, e.g., cDNA expression libraries, peptides, proteins, nucleic acids, antibodies, small organic compounds, hormones, peptidomimetics, PNAs or the like (Milner, Nature Medicine 1 (1995), 879-880; Hupp, Cell 83 (1995), 237-245; Gibbs, Cell 79 (1994), 193-198 and references cited supra).
- genes encoding a putative regulator of the inventive colorectal lesion associated polypeptide and/or which exert their effects up- or downstream the inventive colorectal lesion associated protein may be identified using, for example, insertion mutagenesis using, for example, gene targeting vectors known in the art.
- Said compounds can also be functional derivatives or analogues of known inhibitors or activators.
- Such useful compounds can be for example transacting factors which bind to the inventive colorectal lesion associated protein or regulatory sequences of the gene encoding it. Identification of transacting factors can be carried out using standard methods in the art (see, e.g., Sambrook, supra, and Ausubel, supra). To determine whether a protein binds to the protein itself or regulatory sequences, standard native gel-shift analyses can be carried out. In order to identify a transacting factor which binds to the protein or regulatory sequence, the protein or regulatory sequence can be used as an affinity reagent in standard protein purification methods, or as a probe for screening an expression library.
- nucleic acid molecules which encode polypeptides which interact with the inventive colorectal lesion associated GPCR described above can also be achieved, for example, as described in Scofield (Science 274 (1996), 2063-2065) by use of the so-called yeast "two-hybrid system".
- yeast two-hybrid system
- the polypeptide encoded by a nucleic acid molecule according to the invention or a smaller part thereof is linked to the DNA-binding domain of the GAL4 transcription factor.
- a yeast strain expressing this fusion polypeptide and comprising a lacZ reporter gene driven by an appropriate promoter, which is recognized by the GAL4 transcription factor, is transformed with a library of cDNAs which will express plant proteins or peptides thereof fused to an activation domain.
- a peptide encoded by one of the cDNAs is able to interact with the fusion peptide comprising a peptide of a inventive colorectal lesion associated polypeptide of the invention, the complex is able to direct expression of the reporter gene.
- the nucleic acid molecules according to the invention and the encoded peptide can be used to identify peptides and proteins interacting with the inventive colorectal lesion associated protein. It is apparent to the person skilled in the art that this and similar systems may then further be exploited for the identification of inhibitors of the binding of the inventive colorectal lesion associated proteins.
- the transacting factor modulation of its binding to or regulation of expression of the inventive colorectal lesion associated protein can be pursued, beginning with, for example, screening for inhibitors against the binding of the transacting factor to the protein of the present invention.
- Activation or repression of the inventive colorectal lesion associated proteins could then be achieved in animals by applying the transacting factor (or its inhibitor) or the gene encoding it, e.g. in an expression vector.
- the active form of the transacting factor is a dimer, dominant- negative mutants of the transacting factor could be made in order to inhibit its activity.
- further components in the pathway leading to activation e.g.
- the present invention also relates to the use of the two-hybrid system as defined above for the identification of the inventive colorectal lesion associated polypeptide or activators or inhibitors of the inventive colorectal lesion associated polypeptide.
- the compounds isolated by the above methods also serve as lead compounds for the development of analogue compounds.
- the analogues should have a stabilized electronic configuration and molecular conformation that allows key functional groups to be presented to the inventive colorectal lesion associated polypeptide or its possible receptor in substantially the same way as the lead compound.
- the analogue compounds have spatial electronic properties which are comparable to the binding region, but can be smaller molecules than the lead compound, frequently having a molecular weight below about 2 kD and preferably below about 1 kD.
- Identification of analogue compounds can be performed through use of techniques such as self-consistent field (SCF) analysis, configuration interaction (CI) analysis, and normal mode dynamics analysis.
- SCF self-consistent field
- CI configuration interaction
- normal mode dynamics analysis normal mode dynamics analysis.
- said cell is a cell of or, obtained by a method of the invention or is comprised in the above-described transgenic non-human animal.
- the present invention provides methods for detection and treatment of colorectal lesions, such as e.g. colon carcinomas or adenomas of the colon.
- the present invention provides a method for the detection of disorders characterized by abnormal cell proliferation, such as e.g. cancers based on the determination of the presence or absence and/or the level of expression of the genes associated with colorectal lesions in biological samples.
- the present invention provides a method for treatment of colorectal lesions, such as e.g. cancers using the inventive colorectal lesion associated gene products as therapeutically active agents.
- the invention also provides for therapeutic methods based on the modulation of the activity of the inventive colorectal lesion associated polypeptides.
- Figure 1 Cloned Rsal restriction fragment of the PEP19 (PCP4) gene (Ace. No. U52969) that was spotted in duplicates on nylon membranes and hybridized with the normal colon subtracted probe (N) and the colon carcinoma subtracted probe (T), respectively.
- Figure 2 Cloned Rsal restriction fragment of the ENA78 gene (Ace. No. Af349466) that was spotted in duplicates on nylon membranes and hybridized with the normal colon subtracted probe (N) and the colon carcinoma subtracted probe (T), respectively.
- Figure 3 Cloned Rsal restriction fragment of the elF-1AY gene (Ace. No. Af000987) that was spotted in duplicates on nylon membranes and hybridized with the normal colon subtracted probe (N) and the colon carcinoma subtracted probe (T), respectively.
- Figure 4 Table displaying the genes associated with colorectal lesions. The genes given in this table are differentially expressed in tissue of colorectal tumors; The genes are overexpressed in tumor tissue and not in corresponding normal tissue, (see example 1 and 2) These genes may be used for detection and treatment of colorectal disorders according to the present invention.
- Figure 5 Results of the RT-PCR experiment, (for experimental details see example 2) The figure shows the expression of the FN14 gene in samples of colon carcinomas related to the expression in corresponding normal colon tissue. The y-axis shows the rate of overexpression related to the control expression in normal control tissue
- Figure 6 Cloned Rsal restriction fragment of the inventive GPCR gene that was spotted in duplicates on nylon membranes and hybridized with the normal colon subtracted probe (N) and the colon carcinoma subtracted probe (T), respectively.
- Figure 7 Results of RT PCR experiments for determination of the level of expression of the inventive GPCR in four colon carcinoma samples (T) and the corresponding normal colon tissues (N). For experimental details see Example 3.
- Figure 8 Gel eleetrophoretic analysis of the PCR products obtainable with primers specific for the inventive GPCR In this experiment the various splicing variants (a-d) of the gene are displayed. For experimental details see Example 4.
- Figure 9 Nucleic acid sequences and polypeptide sequences of the inventive GPCR. A) Splicing variants (a), (b), and (c). B) Splicing variant (d) with altered polypeptide sequence. The primers used for the experiment in Figure 8 are underlined.
- Figure 10 Overview of the alternative splicing events of the inventive GPCR
- Figure 11 Immunochemical staining of colorectal tissue using antibodies directed against FAT10; it is visible, that tumor tissue may be stained with antibodies directed against FAT10 using a procedure as described in Example 5. For experimental details see
- Figure 12 Western Blot analysis of tumor tissue from colorectal tumors and of corresponding normal tissue; Antibodies directed against REG1b were used in this experiment; it is visible, that in normal tissue there is no signal for REG1b, whereas in tumour tissue a strong signal for REG1 b may be detected.
- Example 6 Western Blot analysis of tumor tissue from colorectal tumors and of corresponding normal tissue; Antibodies directed against REG1b were used in this experiment; it is visible, that in normal tissue there is no signal for REG1b, whereas in tumour tissue a strong signal for REG1 b may be detected.
- Example 6 The following examples are given for the purpose of illustration only and are not intended to limit the scope of the invention disclosed herein.
- Example 1 Identification of differential expression of genes in human colon tissue versus human colon tumor tissue
- Identification of differentially expressed genes may for example be performed by suppressive subtractive hybridisation method as follows:
- This technique compares two populations of mRNA and provides clones of genes that are expressed in one population but not in the other.
- the applied technique was described in detail in Diatchenko et al., 1996.
- mRNA populations from human colon cancer tissue and normal colon tissue were compared. Specifically, mRNA of the normal colon biopsy was subtracted from mRNA of the colon cancer tissue. The necessary reagents were taken from the PCR-SelectTM cDNA subtraction kit (Clontech) and all steps were performed as described in the manufacturer ' s protocol.
- Subtracted cDNAs were inserted into the pCR2.1 vector and transformed into INV ⁇ F ' cells (Invitrogen).
- the filters were washed twice in 2 x SSC / 0.5% SDS at 68°C for 15 min and twice in 0,1 x SSC / 0.5% SDS at 68°C for 15 min, and subjected to detection using anti-DIG-AP conjugates and CDP-StarTM as chemiluminescent substrate according to the instructions of the DIG DNA Detection Kit (Roche). Blots were exposed to Kodak Biomax MR chemiluminescent film at room temperature for several minutes.
- the genes given in figure 4 have been identified to be differentially expressed in colorectal lesions compared to normal tissue. Examples of the differential screening of the subtracted libraries are shown in figures 1-3. Further more a GPCR encoding gene given in Figure 9 has been identified to be differentially expressed in colorectal lesions compared to normal tissue.
- the GPCR gene is located on chromosome 7p14-15 (clone UWGC:g1564a307, AC005853).
- Example 2 Detection of the level of expression of genes associated with colorectal disorders by RT-PCR
- Samples of adenocarcinomas and adenomas of the colon are used to determine the level of mRNA of the genes given in the table displayed in Figure 4 using semi-quantitative RT PCR. 15 tumor biopsies and samples of 50 adenomas are used in this study.
- Tumors and adenomas are collected, snap frozen, and stored at -80°C. They are verified to be composed predominantly of neoplastic cells by histopathological analysis.
- mRNA is isolated from tumors and patient-matched normal tissue using Qiagen reagents (Qiagen, Hilden, Germany), and single-stranded cDNA is synthesized using Superscript II (Life Technologies, Inc.).
- Quantitative PCR is performed using the 7700 Sequence Detector (TaqmanTM) and the SYBR Green PCR Master- Mix, as described in the manufacturers manual (Applied Biosystems, Foster City, CA). PCR reactions are performed in 25 ⁇ l volumes with a final concentration of 300 nmol for each primer, with 95°C for 15 sec and 60°C for 60 sec, for 40 cycles.
- the example illustrates, that the genes identified herein are suitable for the detection of colorectal lesions by determining the expression level of the respective genes given in figure 4.
- a comparison of the expression level of the particular marker molecules in test tissue to the expression level in normal control tissue reveals whether the test tissue is affected by a colorectal lesion or not.
- Example 3 Detection of the level of expression of the inventive GPCR associated with colorectal disorders by RT-PCR in colorectal samples and samples of lung tissue
- Samples of adenocarcinomas and adenomas of the colon and samples of lung carcinomas are used to determine the level of mRNA of the inventive GPCR using semi-quantitative RT PCR.
- Each 4 tumor biopsies (of the colon and of the lung) and samples of 4 adenomas are used in this study.
- Carcinomas and adenomas are collected, snap frozen, and stored at -80°C. They are verified to be composed predominantly of neoplastic cells by histopathological analysis.
- mRNA is isolated from tumors and patient-matched normal tissue using Qiagen reagents (Qiagen, Hilden, Germany), and single-stranded cDNA is synthesized using Superscript II (Life Technologies, Inc.).
- PCR is performed using the GeneAmp PCR System 9700 (PE Applied Biosystems) and the TitaniumTM Taq PCR kit, as described in the manufacturers manual (Clontech Laboratories, Palo Alto, CA).
- PCR reactions are performed in 25 ⁇ l volumes with a final concentration of 400nM for each primer (5'primer: 5'-AAATTCACAACCCTAATGGGG-3'; 3'primer: 5'-TGTGGTCAACTTTGGTAACTGC-3'), with 95°C for 30 sec, 60°C for 60 sec, and 68°C for 60 sec for 35 cycles.
- Figure 7 shows the results of RT- PCR experiments for 4 different colon carcinomas.
- the GPCR gene identified herein is suitable for the detection of disorders associated with abnormal proliferation of cells such as e.g. colorectal lesions or lung tumors by determining the expression level of the GPCR gene given in Figure 9.
- the present example illustrates that the comparison of the expression level of the particular marker molecules in test tissue to the expression level in normal control tissue may be used to state whether the test tissue is affected by a disorder or not. ( Figure 7)
- the GPCR transcript was found to be overexpressed in colon carcinoma biopsies when compared with normal colon by subtractive hybridization as described in example 1.
- the cloned Rsal restriction fragment of the GPCR is located in the 3' untranslated region of the GPCR gene.
- PCR is performed using the GeneAmp PCR System 9700 (PE Applied Biosystems) and the Advantage2 PCR kit, as described in the manufacturers manual (Clontech Laboratories, Palo Alto, CA).
- PCR reactions are performed in 25 ⁇ l volumes with a final concentration of 400nM for each primer (5'primer: 5'-TCAACCTCCTTCCAGACACC-3'; 3'primer: 5'-TGTGGTCAACTTTGGTAACTGC-3'), with 95°C for 30 sec, 60°C for 60 sec, and 68°C for 4.5 min for 35 cycles.
- PCR products are verified by gel electrophoresis (Figure 8). The results show that four different PCR products are generated (a-d in Figure 8). This indicates the presence of four different splicing variants int the test sample.
- the PCR products are cloned into the pCR2.1 vector and transformed into INV F ' cells (Invitrogen). Individual bacterial transformants were incubated in 100 ⁇ l LB amp (50 ⁇ g/ml) at 37°C for at least 4 hours. Inserts were PCR amplified using 1 ⁇ l of bacterial culture under conditions as described above. Positive clones containing the different splicing variants of the GPCR gene (a-d) were sequenced (MWG Biotech AG, Ebersberg, Germany) from both sides using primers as described above.
- colon carcinoma specific splicing variants do not alter the amino acid sequence of the normal tissue protein ( Figure 9A). However, they represent transcripts with strongly elongated 3' untranslated regions which may lead to dysregulation of the GPCR gene in terms of protein expression, protein localization and protein function in carcinomas.
- Splicing variant (d) alters the amino acid sequence of the normal tissue protein as the C-terminal 50 amino acids are replaced by 28 new amino acids due to a shift in the open reading frame ( Figure 9B). Carcinoma specific alteration of the intracellular domain of a GPCR may lead to dysfunction of the protein in terms of signal transduction, growth control, and apoptosis.
- Sections of formalin fixed, paraffin embedded tissue samples of the colon were immunocytochemically stained using antibodies specific for FAT10.
- the sections were rehydrated through incubation in xylene and graded ethanol, and transferred to Aqua bidest. Antigen Retrieval was carried out with 10mM citrate buffer ( pH 6.0 ) Therefore the slides were heated in a waterbath for 40 min at 95 °C. The slides were cooled down to RT for 20 minutes, transferred to washing buffer ( PBS / 0.1% Tween20 ).
- the samples are incubated with 3% H2O2 for 20 min at RT and afterwards washed in PBS / 0.1% Tween20 for 5 to 10 min.
- the slides were then incubated with the primary antibody, at a concentration of 4 ⁇ g/ml ( for 1 hour at RT, the slides were then rinsed with washing buffer and placed in a fresh buffer bath for 5 min.
- the antibodies employed are directed against the peptide sequences
- the slides were incubated with the secondary antibody (goat anti rabbit-HRP (1 :500). Washing was performed 3 times for 5 minutes. Excess buffer was tapped off and the specimen was covered with 100 ⁇ l of visualization reagent for 30 min at RT. Slides were washed as before, and covered with 200 ⁇ l substrate-chromogen solution (DAB) for 10 min. Then slides were washed as before and counterstained for 3 min in a bath of haematoxylin. Residual haematoxylin was rinsed with distilled water, and specimens were mounted and coverslipped with an aqueous mounting medium.
- DAB substrate-chromogen solution
- the microscopic examination of the slides reveals, that cells immunoreactive with FAT10 can be found in samples, that may microscopically be identified as samples of colorectal carcinoma.
- Example 6 Western Blot analysis of Reglb in lysed tumour tissue
- the clinical material is in a first step solubilzed by boiling (5min, 95°C) in Lammli Protein Sample buffer (100 mM Tris pH.6.8, 2% SDS, 200mM DTT, 0.05% BpB) and insoluble components are spun down.
- Lammli Protein Sample buffer 100 mM Tris pH.6.8, 2% SDS, 200mM DTT, 0.05% BpB
- supernatant protein samples are resolved on a SDS-PAGE (12% Acrylamide) and subsequently transferred to a nitrocellulose membrane by tank blotting (Towbin et al., 1979, Proc Natl Acad Sci;76:4350-4354).
- the membranes are blocked to prevent unspecific antibody binding (10% non fat dry milk in PBS) and subsequently incubated with the specific polyclonal antibody directed against Regl b polypeptides.
- the antibodies employed are directed against the peptide sequences
- the binding of the specific antibody was visualized by Horseradish Peroxidase conjugated secondary reagents (binding to the marker specific antibody) catalysing photon emitting substrates.
- Example 7 ELISA analysis of FAT10, Reglb, GPCR, MC 5, DNAse-X and Claudinl in samples of colorectal carcinoma and of normal control tissue
- Plates are washed 6x with PBS / 0.1% Tween-20 and blocked with PBS / 2%BSA / 0,1%Tween 20 over night at 4°C. Solubilized protein extract from colorectal tumor and corresponding normal tissue samples are dissolved in incubation buffer (PBS, 0,2% BSA, 0.1% Tween -20), and added in triplicates to each well. After 1 h incubation at RT, plates are washed 6x with PBS / 0.1% Tween-20 and incubated with biotinylated detection antibody (each polyclonal antibodies directed against epitopes distinct from those of the capture antibodies) for 1 h at RT.
- biotinylated detection antibody each polyclonal antibodies directed against epitopes distinct from those of the capture antibodies
- the ELISA test shows, that although the marker molecules tested except FAT10 and GPCR would give 100% sensitivity the use of the respective molecules in the ELISA format may be restricted by the fact that none of the tested markers is 100% specific.
- By way of combination of two or more marker molecules enhanced diagnostic value can be achieved. In the presented study by means of a combination of the markers the diagnosis could be confirmed. By combining any two out of the panel (except FAT10 and GPCR) a sufficient high degree of sensitivity to detect all of the tumors in test could be achieved.
- DNAse-X shows 100% sensitivity (70% of the tumors giving strong signals, 30% show immediate signal intensity) with 70% specificity. Critical in this regard might be that 3/10 normal tissues showed weak to itermediate signal intensity using DNAseX as evaluation criterium. Hence the positive predictive value 1 is only 76,9%. In contrast, DNAse-X provides a negative predictive value 2 of 100%. Therefore to increase the positive predictive value of DNAse-X, this marker may be combined with MCM5 (positive predictive value of 83,3%) or Claudinl (positive predictive value of 90,9%). MCM5 and Claudinl also show 100 % sensitivity (in both cases 80% of the tumors give a strong signal and 20% intermediate signal intensity).
- MCM5 with Caludinl and/or DNAse-X would increase the positive predictive value in a test.
- MCM5 and Claudinl show 100% sensitivity but a specificity of 80% and 90% respectively;
- GPCR (70% sensitivity and 70% specificity) and FAT10 (40% sensitivity and 90% specificity) might be suitable as a combination marker with DNAse-X, MCM5 and Claudinl to increase specificity and negative predictive values.
- the markers as presented in this example thus may be combined in sets of two or three or even more for enhanced diagnostic performance in the detection of colorectal lesions.
- the combinations may comprise any of the six markers tested, furthermore any of the markers given in Figure 4 or even any other marker useful for the detection of colorectal lesions.
- true positives positive predictive value ; -r * — t —r-, * _ * r true positives + false positives
- true negatives negative predictive value true negatives + false negatives
- procedure of the present example may be helpful for identifying panels of marker molecules for use in selection of combinations of marker molecules suitable for an ELISA test format.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003268905A AU2003268905A1 (en) | 2002-05-21 | 2003-05-21 | G - protein coupled receptor marker molecules associated with colorectal lesions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20020010273 EP1365030A1 (fr) | 2002-05-21 | 2002-05-21 | Récepteurs couplés aux protéines G (gpcr) comme marqueur associé aux lésions colorectales |
EP02010273.7 | 2002-05-21 | ||
EP02010276.0 | 2002-05-21 | ||
EP20020010276 EP1365242A1 (fr) | 2002-05-21 | 2002-05-21 | Composés pour le diagnostique et le traitement de lésions colorectales |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003097872A2 true WO2003097872A2 (fr) | 2003-11-27 |
WO2003097872A3 WO2003097872A3 (fr) | 2004-07-08 |
Family
ID=29551320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/050185 WO2003097872A2 (fr) | 2002-05-21 | 2003-05-21 | Procede in-vitro permettant de detecter des lesions colorectales |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003268905A1 (fr) |
WO (1) | WO2003097872A2 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005111239A2 (fr) * | 2004-04-30 | 2005-11-24 | Decode Genetics Ehf. | Haplotypes dans le gene homologue de la proteine d'interaction de la thioredoxine humaine (arrdc3) associe a l'obesite |
WO2009077156A1 (fr) * | 2007-12-14 | 2009-06-25 | Oncnosis Pharma A.I.E. | Procédé pour le diagnostic de tumeurs colorectales |
EP2169078A1 (fr) | 2008-09-26 | 2010-03-31 | Fundacion Gaiker | Procédés et kits pour le diagnostic et la stratification du cancer colorectal |
US8068990B2 (en) | 2003-03-25 | 2011-11-29 | Hologic, Inc. | Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids |
WO2013092960A1 (fr) | 2011-12-22 | 2013-06-27 | Fundacion Gaiker | Procédés et kits destinés au diagnostic du cancer colorectal |
US9689874B2 (en) | 2015-04-10 | 2017-06-27 | Applied Proteomics, Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
US10670611B2 (en) | 2014-09-26 | 2020-06-02 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
US10867706B2 (en) | 2010-07-20 | 2020-12-15 | Applied Invention, Llc | Multi-scale complex systems transdisciplinary analysis of response to therapy |
WO2024159559A1 (fr) * | 2023-02-01 | 2024-08-08 | 杭州度安医学检验实验室有限公司 | Marqueur protéique et kit pour le dépistage précoce du cancer colorectal et leur utilisation |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058675A2 (fr) * | 1998-05-14 | 1999-11-18 | Chiron Corporation | Genes humains et produits d'expression genique v |
WO1999064576A2 (fr) * | 1998-06-10 | 1999-12-16 | Bayer Corporation | Nouveaux genes humains et produits d'expression genique |
WO2000037643A2 (fr) * | 1998-12-23 | 2000-06-29 | Corixa Corporation | Composes destines a l'immunotherapie et au diagnostic du cancer du colon et methodes d'utilisation |
WO2001096388A2 (fr) * | 2000-06-09 | 2001-12-20 | Corixa Corporation | Compositions et procedes servant a traiter et a diagnostiquer le cancer du colon |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001048188A1 (fr) * | 1999-12-28 | 2001-07-05 | Helix Research Institute | Nouveaux recepteurs couples a la proteine de liaison a guanosine triphosphate, leurs genes, leur preparation et leur utilisation |
US20020062013A1 (en) * | 1999-12-28 | 2002-05-23 | Peter Lind | Novel G protein-coupled receptors |
US7250272B2 (en) * | 2000-10-13 | 2007-07-31 | Takeda Pharmaceutical Company Limited | G protein-coupled receptor protein and DNA thereof |
-
2003
- 2003-05-21 AU AU2003268905A patent/AU2003268905A1/en not_active Abandoned
- 2003-05-21 WO PCT/EP2003/050185 patent/WO2003097872A2/fr not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058675A2 (fr) * | 1998-05-14 | 1999-11-18 | Chiron Corporation | Genes humains et produits d'expression genique v |
WO1999064576A2 (fr) * | 1998-06-10 | 1999-12-16 | Bayer Corporation | Nouveaux genes humains et produits d'expression genique |
WO2000037643A2 (fr) * | 1998-12-23 | 2000-06-29 | Corixa Corporation | Composes destines a l'immunotherapie et au diagnostic du cancer du colon et methodes d'utilisation |
WO2001096388A2 (fr) * | 2000-06-09 | 2001-12-20 | Corixa Corporation | Compositions et procedes servant a traiter et a diagnostiquer le cancer du colon |
Non-Patent Citations (9)
Title |
---|
CARIM L ET AL: "CLONING, EXPRESSION, AND MAPPING OF PDCD9, THE HUMAN HOMOLOG OF GALLUS GALLUS PRO-APOPTOTIC PROTEIN P52" CYTOGENETICS AND CELL GENETICS, BASEL, CH, vol. 87, no. 1/2, 1999, pages 85-88, XP008009879 ISSN: 0301-0171 * |
DATABASE EMBL [Online] XP002217848 Database accession no. ABK69599 & DATABASE EMBL [Online] Database accession no. AAU96348 & WO 02/31145 A (MIYAJIMA NOBUYUKI) 18 April 2002 (2002-04-18) * |
DATABASE EMBL [Online] XP002217849 Database accession no. AX188714 & DATABASE EMBL [Online] Database accession no. AX188701 & WO 01/48015 A (UPJOHN CO) 5 July 2001 (2001-07-05) * |
DATABASE EMBL [Online] XP002217850 Database accession no. AAH73501 & DATABASE EMBL [Online] Database accession no. AAG64118 & WO 01/48188 A (HELIX RES INST) 5 July 2001 (2001-07-05) * |
DATABASE GENBANK [Online] 4 March 2000 (2000-03-04), XP002229355 retrieved from EBI Database accession no. AW080854 * |
HIGGINS P ET AL: "PROTEIN IN COLONIC BIOPSIES OF SUBJECTS WITH AND WITHOUT COLONIC NEOPLASIA" GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, 1995, page A480, XP008009936 ISSN: 0016-5085 * |
LIU Y-C ET AL: "A MHC-encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly checkpoint protein MAD2" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 8, 13 April 1999 (1999-04-13), pages 4313-4318, XP002223380 ISSN: 0027-8424 * |
REN J ET AL: "IDENTIFICATION OF DIUBIQUITIN AS A CANCER-ASSOCIATED PROTEIN" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 43, no. 819, March 2002 (2002-03), page 819, XP008013173 ISSN: 0197-016X * |
ZHANG ZHONGHUA ET AL: "Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 20, no. 33, 2001, pages 4450-4456, XP002218563 ISSN: 0950-9232 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8068990B2 (en) | 2003-03-25 | 2011-11-29 | Hologic, Inc. | Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids |
WO2005111239A2 (fr) * | 2004-04-30 | 2005-11-24 | Decode Genetics Ehf. | Haplotypes dans le gene homologue de la proteine d'interaction de la thioredoxine humaine (arrdc3) associe a l'obesite |
WO2005111239A3 (fr) * | 2004-04-30 | 2006-05-04 | Decode Genetics Ehf | Haplotypes dans le gene homologue de la proteine d'interaction de la thioredoxine humaine (arrdc3) associe a l'obesite |
WO2009077156A1 (fr) * | 2007-12-14 | 2009-06-25 | Oncnosis Pharma A.I.E. | Procédé pour le diagnostic de tumeurs colorectales |
EP2169078A1 (fr) | 2008-09-26 | 2010-03-31 | Fundacion Gaiker | Procédés et kits pour le diagnostic et la stratification du cancer colorectal |
US10867706B2 (en) | 2010-07-20 | 2020-12-15 | Applied Invention, Llc | Multi-scale complex systems transdisciplinary analysis of response to therapy |
WO2013092960A1 (fr) | 2011-12-22 | 2013-06-27 | Fundacion Gaiker | Procédés et kits destinés au diagnostic du cancer colorectal |
US10670611B2 (en) | 2014-09-26 | 2020-06-02 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
US9689874B2 (en) | 2015-04-10 | 2017-06-27 | Applied Proteomics, Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
WO2024159559A1 (fr) * | 2023-02-01 | 2024-08-08 | 杭州度安医学检验实验室有限公司 | Marqueur protéique et kit pour le dépistage précoce du cancer colorectal et leur utilisation |
Also Published As
Publication number | Publication date |
---|---|
AU2003268905A8 (en) | 2003-12-02 |
WO2003097872A3 (fr) | 2004-07-08 |
AU2003268905A1 (en) | 2003-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101828290B1 (ko) | 자궁내막암 마커 | |
US6682890B2 (en) | Methods of diagnosing and determining prognosis of colorectal cancer | |
JP2001513886A (ja) | 前立腺ガンの免疫診断のための化合物およびそれらの使用方法 | |
CA2511907A1 (fr) | Compositions et procede permettant de diagnostiquer et de traiter les cancers du colon | |
US20020076735A1 (en) | Diagnostic and therapeutic methods using molecules differentially expressed in cancer cells | |
US20140357518A1 (en) | Methods and Compositions for the Treatment and Diagnosis of Thyroid Cancer | |
CA2510150C (fr) | Composes et methodes de detection de carcinomes et leurs lesions precurseurs | |
JP2002515591A (ja) | 結腸癌を診断し、モニターし、そして病期決定する新規方法 | |
WO2003073911A2 (fr) | Methode et composition pour detection et traitement du cancer du sein | |
WO2003097872A2 (fr) | Procede in-vitro permettant de detecter des lesions colorectales | |
US6387697B1 (en) | Compositions for treatment and diagnosis of breast cancer and methods for their use | |
US8216792B2 (en) | Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene | |
EP1338606A1 (fr) | Molecules d'acide nucleique codant de HERV-H polypeptide de diagnostic du cancer colorectal | |
US7883896B2 (en) | Marker molecules associated with lung tumors | |
EP1365030A1 (fr) | Récepteurs couplés aux protéines G (gpcr) comme marqueur associé aux lésions colorectales | |
US20050272038A1 (en) | Compositions and methods for diagnosis and therapy of cancers | |
EP1426442A1 (fr) | Marqueurs associes au lesions colorectales | |
EP1365242A1 (fr) | Composés pour le diagnostique et le traitement de lésions colorectales | |
WO2002016939A2 (fr) | Procedes de diagnostic du cancer, compositions et procedes de depistage de modulateurs du cancer | |
US20050153352A1 (en) | Cancer specific gene MG20 | |
CA2431313A1 (fr) | Procede de diagnostic du cancer du sein et/ou du cancer colorectal, compositions, et procedes de criblage de modulateurs du cancer du sein et/ou du cancer colorectal | |
JP2007503826A (ja) | 乳癌のリスクの診断 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |